Breathing new life into an old target: pulmonary disease drugs for Parkinson's disease therapy.

Journal Article (Journal Article)

Increases in α-synuclein protein expression are suspected to increase the risk of the development of Parkinson's disease (PD). A recent study has demonstrated that β2-adrenergic receptor (β2AR) agonists decrease histone acetylation in the α-synuclein gene and suppress transcription. Coupled with the anti-inflammatory effects that are associated with β2AR activation, this two-pronged attack holds promise for PD treatment and the development of new therapeutic approaches for this disease.

Full Text

Duke Authors

Cited Authors

  • Abdelmotilib, H; West, AB

Published Date

  • October 19, 2017

Published In

Volume / Issue

  • 9 / 1

Start / End Page

  • 88 -

PubMed ID

  • 29052536

Pubmed Central ID

  • PMC5649055

Electronic International Standard Serial Number (EISSN)

  • 1756-994X

Digital Object Identifier (DOI)

  • 10.1186/s13073-017-0483-4

Language

  • eng

Conference Location

  • England